EUVIMEDEUVIMED entdecken
Kohortenstudie

Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study

Yonghong Li, Yirui Liu, Yi Peng, Jing Tang, Xiaobing Li

Oncology · 2025

DOI: 10.1159/000546834 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Oncology, 2025. Verfasst von Yonghong Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First People's Hospital of Tianmen, Tianmen, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Quinolines, Indoles, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In this study, we aimed to evaluate the efficacy and safety of the combination therapy with chemotherapy and anlotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations who exhibit primary resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).

Methods

Clinical data were collected from patients with advanced NSCLC harboring EGFR mutations and exhibiting primary resistance to EGFR-TKI, who were treated with a combination of chemotherapy and anlotinib. The primary endpoints were overall response rate (ORR), progression-free survival (PFS), disease control rate, overall survival (OS), and treatment-related adverse events (AEs).

Results

A total of 34 patients with advanced NSCLC harboring EGFR mutations and exhibiting primary resistance to EGFR-TKI were enrolled. The ORR and DCR for the treatment with chemotherapy plus anlotinib were 32.35% and 64.71%, respectively. The median PFS and OS were 5 months and 9 months, respectively. Compared to patients with EGFR exon 19 deletion mutations, those with EGFR exon 21 L858R mutations derived greater benefit from the treatment (mPFS = 4.0 months vs. 5.0 months, p < 0.05; mOS = 9.0 months vs. 10.0 months, p < 0.05). The common AEs were myelosuppression, hypertension, proteinuria, and hand-foot syndrome. Most AEs were mild and well tolerated. These findings suggest that chemotherapy combined with anlotinib may be a promising strategy to overcome primary resistance to EGFR-TKIs in patients with advanced NSCLC.

Conclusion

The combination of chemotherapy and anlotinib appears to be an effective and well-tolerated treatment strategy in patients with advanced NSCLC exhibiting primary resistance to EGFR-TKIs. Further studies are warranted to validate these findings and investigate long-term clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungQuinolinesIndolesLung NeoplasmsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleErbB ReceptorsMiddle AgedAgedRetrospective StudiesDrug Resistance, NeoplasmMutationAdultProgression-Free SurvivalTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

AnlotinibChemotherapyEpidermal growth factor receptor-tyrosine kinase inhibitorNon-small cell lung cancerPrimary resistance

Substanzen

anlotinibErbB ReceptorsQuinolinesIndolesProtein Kinase InhibitorsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, The First People's Hospital of Tianmen, Tianmen, China.
  • Department of Nursing, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Lymphoma, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, lixiaobing0629@126.com.

Zitieren

APA

Li, Y., Liu, Y., Peng, Y., Tang, J., & Li, X. (2025). Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study. Oncology. https://doi.org/10.1159/000546834

Vancouver

Li Y, Liu Y, Peng Y, Tang J, Li X. Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study. Oncology. 2025. doi:10.1159/000546834

BibTeX
@article{Li2025,
  author = {Li, Yonghong and Liu, Yirui and Peng, Yi and Tang, Jing and Li, Xiaobing},
  title = {Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000546834}
}
Kostenlos starten →